Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Hematopoiesis01:21

Hematopoiesis

The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of an optimal absolute lymphocyte count at leukapheresis in patients with lymphoma treated with CART.

Blood immunology & cellular therapy·2026
Same author

Donor-specific HLA mismatch: haploidentical versus 7/8 mismatched unrelated donor hematopoietic cell transplantation with PTCy.

Bone marrow transplantation·2026
Same author

Impact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromes.

Blood cancer journal·2026
Same author

Impact of age on outcomes after CD19 CAR T-cell therapy for large B-cell lymphomas.

Blood neoplasia·2026
Same author

Salvage high-dose chemotherapy and autologous stem cell transplant consolidation following relapse after CAR-T cell for large B-cell lymphoma.

Haematologica·2026
Same author

Phase 1B pilot study of itacitinib with alemtuzumab in patients with T-cell prolymphocytic leukemia.

Blood neoplasia·2026
Same journal

Tracking Synthetic Adhesins on Bacterial Surfaces with Immunofluorescence Microscopy.

Methods in molecular biology (Clifton, N.J.)·2026
Same journal

Post-Selection Methods for Analyzing mRNA Display Selections and Optimization of Hits.

Methods in molecular biology (Clifton, N.J.)·2026
Same journal

High-Performance Computing in Tandem Mass Spectrometry (MS/MS) Peptide Identification.

Methods in molecular biology (Clifton, N.J.)·2026
Same journal

Engineering and Adapting Disulfide-Containing Proteins to Enable Intracellular Functionality.

Methods in molecular biology (Clifton, N.J.)·2026
Same journal

AI-Driven Protein Research: From Prediction to Design.

Methods in molecular biology (Clifton, N.J.)·2026
Same journal

Methods for the In Vitro Selection of Protein and Peptide Libraries Using mRNA Display.

Methods in molecular biology (Clifton, N.J.)·2026
See all related articles

Related Experiment Video

Updated: May 19, 2026

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications
08:32

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications

Published on: August 9, 2022

Hematopoietic stem cell mobilization with G-CSF.

Chitra Hosing1

  • 1Department of Stem Cell Transplantation and Cell Therapy, M.D. Anderson Cancer Center, Houston, TX, USA. cmhosing@mdanderson.org

Methods in Molecular Biology (Clifton, N.J.)
|August 15, 2012
PubMed
Summary
This summary is machine-generated.

Peripheral blood stem cells (PBSCs) are now preferred for transplants over bone marrow due to faster recovery and lower mortality. This chapter details PBSC mobilization in patients and donors using G-CSF.

More Related Videos

Derivation of Hematopoietic Stem Cells from Murine Embryonic Stem Cells
22:06

Derivation of Hematopoietic Stem Cells from Murine Embryonic Stem Cells

Published on: February 25, 2007

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Related Experiment Videos

Last Updated: May 19, 2026

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications
08:32

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications

Published on: August 9, 2022

Derivation of Hematopoietic Stem Cells from Murine Embryonic Stem Cells
22:06

Derivation of Hematopoietic Stem Cells from Murine Embryonic Stem Cells

Published on: February 25, 2007

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Area of Science:

  • Hematology
  • Transplantation Medicine
  • Cellular Therapy

Background:

  • Peripheral blood stem cells (PBSCs) have largely replaced bone marrow as the primary source for autologous stem cell transplantation.
  • Increasingly, PBSCs are also utilized for allogeneic transplantation.
  • This shift is driven by improved post-transplant recovery and reduced mortality rates compared to bone marrow transplants.

Purpose of the Study:

  • To describe the process of peripheral blood stem cell mobilization.
  • To cover mobilization techniques in both autologous transplant patients and allogeneic donors.
  • To highlight the use of granulocyte-colony stimulating factor (G-CSF) in PBSC collection.

Main Methods:

  • Mobilization of PBSCs using G-CSF administration.
  • Collection of PBSCs on an outpatient basis.
  • Description of mobilization protocols for autologous and allogeneic settings.

Main Results:

  • PBSC transplantation is associated with faster granulocyte and platelet recovery post-transplant.
  • Lower regimen-related and transplant-related mortality observed with PBSC transplants compared to bone marrow.
  • PBSCs can be harvested efficiently without general anesthesia.

Conclusions:

  • Cytokine-mobilized PBSCs are the standard for autologous transplantation and increasingly for allogeneic transplantation.
  • G-CSF is a key agent for mobilizing PBSCs for both patient and donor collections.
  • The advantages of PBSCs include rapid engraftment, reduced mortality, and simpler, outpatient-based collection.